Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Limited, has unveiled an $80 million investment to expand its Lexington, Kentucky facility. The expansion aims to enhance the site’s production capabilities for sterile injectable drug products, including sterile compounding, liquid filling, and lyophilization.
The plan will add 24,000 square feet of manufacturing space, introduce state-of-the-art machinery such as new filling lines, two commercial-size lyophilizers, a special capping machine, and an external vial washer. This expansion is expected to significantly boost production capacity, with the Lexington site projected to increase from 104 product batches annually to over 240 batches once the project is completed by Q1 of 2027.
Nandini Piramal, Chairperson of Piramal Pharma Ltd., noted, “This expansion represents a strategic investment in the future of Piramal Pharma, positioning the Lexington site as a key player in the rapidly expanding injectables market.”
Peter DeYoung, Chief Executive Officer of Global Pharma, emphasized the growing demand for injectables and how the expansion will enhance Piramal’s ability to serve clients throughout the product lifecycle. The investment is also set to create over 40 full-time jobs, contributing to the local economy.
The expansion further cements Piramal Pharma’s role as a key player in the global biologic manufacturing market, while also strengthening its presence in the fast-growing injectables segment.
